• Hiromitsu Takizawa, Kazuya Kondo, Hiroaki Toba, Koichiro Kajiura, Abdellah Hamed Khalil Ali, Shoji Sakiyama, and Akira Tangoku.
• Department of Thoracic, Endocrine Surgery, and Oncology, University of Tokushima Graduate School, Tokushima, Japan. htakizawa@clin.med.tokushima-u.ac.jp
• J. Thorac. Cardiovasc. Surg.. 2012 Jul 1;144(1):94-9.

ObjectiveThe objective of the present study was to assess the safety and feasibility of computed tomography lymphography by transbronchial injection of a water-soluble extracellular computed tomography contrast agent.MethodsFrom April 2010 to May 2011, patients with clinical stage I non-small cell lung cancer who were candidates for lobectomy were enrolled in the present study. An ultrathin bronchoscope was inserted to the target bronchus under the guidance of virtual bronchoscopic navigation images. Computed tomography images of the chest were obtained 0.5 and 5 minutes after 2 or 3 mL of iopamidol was injected through a microcatheter. Sentinel nodes were identified when the maximum computed tomography attenuation value of the lymph nodes on the postcontrast computed tomography images increased by 30 Hounsfield units or more compared with the precontrast images. Patients underwent lobectomy with standard lymph node dissection.ResultsThe ultrathin bronchoscope could access the targeted bronchus, and iopamidol was delivered into the peritumoral area in all 13 patients without any complications. Sentinel nodes were identified in 12 (92.3%) of the 13 patients. The average number of sentinel nodes was 1.5 (range, 1-2). Pathologic examination revealed metastatic lymph nodes in 2 patients. Metastatic nodes were included with the sentinel nodes.ConclusionsComputed tomography lymphography by transbronchial injection of iopamidol was a safe and feasible method to identify the sentinel nodes in patients with clinical stage I non-small cell lung cancer.Copyright © 2012 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

29 keywords...

hide…